Autoimmunity reviews最新文献

{"title":"Monoclonal Gammopathy of Rheumatologic Significance (MGRhS): a systemic vision of clonal disorders with multiple organ involvement","authors":"Luca Quartuccio ,&nbsp;Valeria Manfrè ,&nbsp;Elena Treppo ,&nbsp;Fabio Perrotta ,&nbsp;Gaafar Ragab ,&nbsp;Andreas Goules ,&nbsp;Ennio Lubrano","doi":"10.1016/j.autrev.2025.103895","DOIUrl":"10.1016/j.autrev.2025.103895","url":null,"abstract":"<div><div>Monoclonal gammopathy (MG) encompasses a spectrum of conditions ranging from benign to malignant clonal B-cell proliferations. While MG is traditionally associated with hematologic malignancies, its role in autoimmune and rheumatologic diseases is increasingly recognized. This review proposes the novel concept of <em>“monoclonal gammopathy of rheumatologic significance (MGRhS)”</em> that refers to a non-malignant or pre-malignant systemic condition related to a monoclonal immunoglobulin and clonal B cells, capable of producing multi-organ damage or influencing the therapeutic management of rheumatologic diseases.</div><div>MG of clinical significance is characterized by the production of monoclonal proteins causing organ damage and modulating immune responses. These proteins contribute to rheumatologic conditions or peculiar phenotypes, including cryoglobulinemic vasculitis, Sjögren's disease, and other autoimmune disorders. The review explores pathogenic mechanisms linking MG with these diseases, emphasizing early detection and accurate classification to guide therapeutic strategies.</div><div>The manuscript addresses the implications of incidental MG detection in rheumatologic patients, particularly in the context of biologic therapies. Practical guidance is provided on identifying MGRhS, assessing its impact, and tailoring management to prevent complications.</div><div>This analysis aims to advance understanding of MGRhS as a distinct clinical entity, encouraging a multidisciplinary approach to its management. The integration of novel diagnostic tools and targeted therapies is essential to improve outcomes and address the complexity of this condition.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 11","pages":"Article 103895"},"PeriodicalIF":8.3,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Specialized pro-resolving mediators and autoimmunity: Recent insights and future perspectives","authors":"Marta Vomero ,&nbsp;Ludovica Lamberti ,&nbsp;Erika Corberi ,&nbsp;Damiano Currado ,&nbsp;Annalisa Marino ,&nbsp;Onorina Berardicurti ,&nbsp;Marina Fava ,&nbsp;Alessandro Leuti ,&nbsp;Mauro Maccarrone ,&nbsp;Roberto Giacomelli ,&nbsp;Luca Navarini","doi":"10.1016/j.autrev.2025.103896","DOIUrl":"10.1016/j.autrev.2025.103896","url":null,"abstract":"<div><div>Inflammation is a response to injuries involving multiple cellular and molecular mechanisms. Different stimuli, such as trauma or microbial invasion, trigger an acute inflammatory response consisting, at least in principle, of two phases: initiation and resolution. Although the acute phase of inflammatory response represents a protective and usually self-limited mechanism, it can sometimes persist and evolve into chronic inflammation, a key driver in the development of many rheumatic and autoimmune diseases. The biosynthesis of specialized pro-resolving mediators (SPMs) orchestrates the resolution phase of inflammation, leading to the shutdown of phlogosis, tissue damage repair, and restoration of homeostasis. Dysregulation in SPMs biosynthesis or receptor expression and signalling are related to impaired viruses' clearance and adaptive immune response. Emerging knowledge on the involvement of SPMs in the development and progression of rheumatic diseases is arising. An altered SPM profile has been observed in different rheumatic diseases, including Rheumatoid Arthritis, Systemic Lupus Erythematosus, Adult-onset Still's Disease, Systemic Sclerosis, and Sjögren's Syndrome. Considering the anti-inflammatory and pro-resolving roles of these molecules, the possible use of synthetic SPMs and fish oil supplements, a crucial source of SPMs precursors DHA, DPA and EPA, in patients affected by chronic inflammatory diseases, is emerging.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 11","pages":"Article 103896"},"PeriodicalIF":8.3,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144759029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intersecting paths between autoimmunity and bone marrow fibrosis: the case of autoimmune myelofibrosis.","authors":"Francesco Carubbi ,&nbsp;Alessia Alunno ,&nbsp;Elisa Matone ,&nbsp;Alessandro Lucchesi ,&nbsp;Gerardo Musuraca ,&nbsp;Claudio Ferri","doi":"10.1016/j.autrev.2025.103893","DOIUrl":"10.1016/j.autrev.2025.103893","url":null,"abstract":"<div><div>Bone marrow fibrosis is frequently observed in patients with haematological malignancies including myeloproliferative neoplasm (MPNs). The most common cause of BMF is the BCR-ABL-negative MPN primary myelofibrosis (PMF) however, BMF may also be caused by a variety of non-neoplastic disorders such as infections, endocrine diseases and autoimmune diseases (ADs). Autoimmune myelofibrosis (AIMF) is a type of BMF associated with either a fully blown AD (secondary AIMF) or serological signs of autoimmunity without an overt AD (primary AIMF). Although isolated case reports and case series have been published, AIMF remains a poorly recognized disorder. Therefore, we performed a scoping review and critically appraised the literature on AIMF pathogenesis, diagnosis and treatment with a particular focus on similarities and differences between AIMF and PMF.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 11","pages":"Article 103893"},"PeriodicalIF":8.3,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144739565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding the effects of Janus kinase inhibitors on the cardiovascular system in comparison to main biological DMARDs in rheumatoid arthritis","authors":"Aliki Zavoriti,&nbsp;Pierre Miossec","doi":"10.1016/j.autrev.2025.103892","DOIUrl":"10.1016/j.autrev.2025.103892","url":null,"abstract":"<div><div>Rheumatoid arthritis (RA) is linked to increased cardiovascular (CV) risk, as is typical for systemic inflammation. The systemic effects of inflammatory cytokines induce vascular dysfunction, leading to thrombosis and other CV diseases. Reducing inflammation should attenuate this risk. For several decades, biologics against a single cytokine, such as TNF inhibitors and IL-6 receptor blockers seem to support this, demonstrating excellent control of RA and reduction of CV events. The Janus kinase inhibitors (JAKi) have been approved more recently. By inhibiting the JAK-STAT pathway, they can simultaneously block the function of multiple cytokines. Unlike biologics, JAKi are associated with increased risk of adverse CV events in high-risk RA patients. This review suggests biological mechanisms that could explain the worse CV outcomes with JAKi compared to biologics. Among the key pro-inflammatory cytokines, IFNγ, IL-6 and IL-23 use directly the JAK-STAT pathway, whereas IL-17, TNF and IL-1β do not, lacking JAK-related receptors. Nevertheless, these non-JAK-dependent cytokines can still influence the JAK-STAT pathway to promote vascular effects in an indirect fashion. Moreover, IL-17 and TNF specifically when combined, exert major pro-coagulant and pro-thrombotic effects on vessels independently of JAKs. As a result, JAKi might not block these pathways and even upregulate them, at high concentrations, leading to increased thrombotic risk. Finally, new research shows that JAKi cannot prevent the increase in adhesion and coagulation molecules as well as the deficiency in physiological anti-coagulant proteins triggered by TNF and IL-17 on endothelial cells. Increased efforts to control CV risk factors are critical in this context.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 11","pages":"Article 103892"},"PeriodicalIF":8.3,"publicationDate":"2025-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144726966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Primordial and primary prevention in rheumatological diseases: The time has come","authors":"Laura Scagnellato ,&nbsp;Mariangela Salvato ,&nbsp;Luca Iorio,&nbsp;Beatrice Moccaldi,&nbsp;Alessandro Giollo,&nbsp;Elisabetta Zanatta,&nbsp;Roberto Padoan,&nbsp;Roberta Ramonda,&nbsp;Andrea Doria","doi":"10.1016/j.autrev.2025.103891","DOIUrl":"10.1016/j.autrev.2025.103891","url":null,"abstract":"<div><div>Rheumatological, immune-mediated diseases (RDs) impose a substantial global burden, especially on women of working age, resulting in chronic disability and escalating healthcare utilisation. Despite therapeutic advances, the incidence of RDs is rising, and no definitive cure exists. Emerging evidence highlights the potential of early-stage interventions, such as addressing preclinical phases of diseases to delay or prevent disease onset. Modifiable risk factors, such as tobacco use, obesity, diet, infections, mechanical strain, and other environmental exposures (e.g., air pollution and ultraviolet radiation), offer clear targets for intervention. Despite increasing efforts in producing high-quality studies for each rheumatological condition, current evidence supports the global promotion of a healthy lifestyle with a balanced diet, regular physical activity and vaccinations, vitamin D supplementation, and minimisation of excessive infectious, mechanical and psychosocial strain. However, to stimulate stakeholders and policymakers in investing and developing strategies for primary prevention, further interventional trials are warranted on at-risk populations such as first-degree relatives of rheumatological patients and asymptomatic autoantibody carriers. Indeed, besides encouraging experiments in rheumatoid arthritis and psoriatic arthritis, where research has reached the adolescent stage, research in disease interception is still in its infancy for most rheumatological conditions.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 9","pages":"Article 103891"},"PeriodicalIF":8.3,"publicationDate":"2025-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144722863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiovascular risk in psoriatic arthritis: How can we manage it?","authors":"Fabiola Atzeni ,&nbsp;Javier Rodríguez-Carrio ,&nbsp;Alessandra Alciati ,&nbsp;Angelo Tropea ,&nbsp;Antonio Marchesoni","doi":"10.1016/j.autrev.2025.103889","DOIUrl":"10.1016/j.autrev.2025.103889","url":null,"abstract":"<div><div>It is now widely recognized that patients with psoriatic arthritis (PsA) have a higher risk of cardiovascular disease (CVD) when compared with the general population. A number of factors contribute to this increased risk. Skin and articular inflammation have been shown to be independently associated with CVD in PsA patients. Metabolic syndrome and all its components are significantly more frequent in PsA patients than in healthy populations. Depression, which is not uncommon in psoriatic subjects, seems to increase the CV risk. Finally, corticosteroids and non-steroidal anti-inflammatory drugs, which are often used for the treatment of PsA, have a well-known pro-atherosclerotic effect.</div><div>Therefore, in PsA patients the CV risk should be regularly estimated, using validated scoring instruments and appropriate techniques of vascular assessment when needed. Instrument choice and usefulness in PsA populations are still under debate. Patients at high risk should be treated addressing all the risk factors and tightly monitored. Abrogation or, at least, reduction of skin and articular inflammation, appropriate treatment of the metabolic abnormalities, and modifications of unhealthy life habits are the measures that can substantially improve the CV outcome of the patients with PsA. Cooperation of different specialists may be needed to optimize the management of the individual patient. Artificial intelligence applications, novel biomarkers and new care approaches, including treatment strategies and decision-making processes, may be considered in the PsA setting.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 11","pages":"Article 103889"},"PeriodicalIF":8.3,"publicationDate":"2025-07-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144717296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Social determinants of health and disparities across the Patient pathway in Systemic Lupus Erythematosus: a narrative review","authors":"Daniel Guimarães de Oliveira ,&nbsp;Zoe Karakikla-Mitsakou ,&nbsp;Lena Koskina ,&nbsp;Laurent Arnaud","doi":"10.1016/j.autrev.2025.103887","DOIUrl":"10.1016/j.autrev.2025.103887","url":null,"abstract":"<div><h3>Objective</h3><div>Systemic Lupus Erythematosus (SLE) is a complex, chronic autoimmune disease with significant heterogeneity in its presentation and progression. Social determinants of health (SDH), including socioeconomic factors, health literacy and access to care, among others, can shape SLE outcomes. This review explores the impact and interaction of these factors across the entire lupus patient pathway – from presentation to therapeutic management and outcomes - and proposes targeted solutions to improve health equity and patient outcomes in SLE.</div></div><div><h3>Methods</h3><div>Narrative review, synthesizing findings from peer-reviewed studies published in the last decade, focusing on SDH influencing SLE outcomes.</div></div><div><h3>Results</h3><div>SDH were found to consistently influence the entirety of the SLE patient pathway. Lupus patients from lower socioeconomic backgrounds experience increased diagnostic delay, worse damage accrual and higher mortality rates. Health literacy emerged as a critical factor, with tailored educational interventions shown to improve therapeutic adherence. Geographic disparities were also significant, with persons living in rural areas reporting reduced access to specialist care compared to urban counterparts. Interventions addressing financial barriers, transportation assistance and remote healthcare options demonstrated potential to improve access and outcomes. Additional approaches are proposed, that take into account the intersection of multiple vulnerabilities, their correlation and their interaction with individual lupus characteristics, which result in cumulative effects on disease severity.</div></div><div><h3>Conclusions</h3><div>Social determinants of health have a profound and measurable impact on SLE outcomes, highlighting the need for multidisciplinary approaches to reduce disparities. Evidence supports targeted interventions aimed at answering local and individual patient contexts, but also multi-level policy changes that address the complexity of these determinants' intersections, to reduce disparities and improve lupus patient outcomes overall. Further studies are critically needed to understand the broader geographic and cultural implications of these social determinants, and longitudinal research should prioritize evaluating the implementation and scalability of strategies addressing these factors.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 10","pages":"Article 103887"},"PeriodicalIF":9.2,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144703269","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring vaccine safety and adverse events in major autoimmune diseases","authors":"Shabnam Sodagari ,&nbsp;Nassim Sodagari","doi":"10.1016/j.autrev.2025.103857","DOIUrl":"10.1016/j.autrev.2025.103857","url":null,"abstract":"<div><div>This study evaluates post-vaccination adverse events by analyzing a large dataset of patients with major autoimmune diseases, including Hashimoto’s <span><math><mrow><mi>n</mi><mo>=</mo><mn>26</mn><mo>,</mo><mn>330</mn></mrow></math></span>; Rheumatoid Arthritis <span><math><mrow><mi>n</mi><mo>=</mo><mn>9</mn><mo>,</mo><mn>251</mn></mrow></math></span>; psoriasis <span><math><mrow><mi>n</mi><mo>=</mo><mn>5</mn><mo>,</mo><mn>589</mn></mrow></math></span>; Systemic Lupus Erythematosus <span><math><mrow><mi>n</mi><mo>=</mo><mn>4</mn><mo>,</mo><mn>208</mn></mrow></math></span>; Inflammatory Bowel Disease <span><math><mrow><mi>n</mi><mo>=</mo><mn>5</mn><mo>,</mo><mn>831</mn></mrow></math></span>; type 1 diabetes <span><math><mrow><mi>n</mi><mo>=</mo><mn>2</mn><mo>,</mo><mn>235</mn></mrow></math></span>; vasculitis <span><math><mrow><mi>n</mi><mo>=</mo><mn>466</mn></mrow></math></span>; Guillain-Barré Syndrome <span><math><mrow><mi>n</mi><mo>=</mo><mn>185</mn></mrow></math></span>; Immune Thrombocytopenic Purpura <span><math><mrow><mi>n</mi><mo>=</mo><mn>623</mn></mrow></math></span>; ankylosing spondylitis <span><math><mrow><mi>n</mi><mo>=</mo><mn>926</mn></mrow></math></span>; Sjögren’s syndrome <span><math><mrow><mi>n</mi><mo>=</mo><mn>269</mn></mrow></math></span>; psoriatic arthritis <span><math><mrow><mi>n</mi><mo>=</mo><mn>2</mn><mo>,</mo><mn>355</mn></mrow></math></span>; polymyositis <span><math><mrow><mi>n</mi><mo>=</mo><mn>169</mn></mrow></math></span>; dermatomyositis <span><math><mrow><mi>n</mi><mo>=</mo><mn>130</mn></mrow></math></span>. Our objective is not to refute the importance of vaccines, but to raise awareness about potential risks observed in autoimmune patients by analyzing CDC (Centers for Disease Control and Prevention) data. The sex distribution analysis in vaccine adverse events highlights a consistent female predominance across most autoimmune conditions. We designed machine learning predictive classification models by identifying key predictors to predict severe adverse events (hospitalization or death) following vaccination based on clinical and demographic predictors including age, sex, vaccine type, dose series, and vaccine route. Our models identified distinct risk profiles for severe events across diseases. Example AUC values ranged from 0.90 for dermatomyositis and GBS to 0.98 for Psoriatic Arthritis with accuracy 96% observed for ankylosing spondylitis. Vasculitis and Sjögren’s showed peak precision scores, while polymyositis showed peak recall (97%). Moreover, the reported adverse events in the first week and after the 6th week of vaccine administration are one order of magnitude larger than reported incidents in other time intervals for all diseases. Understanding these differences can inform safer vaccination strategies. We recognize the essential public health role of vaccines and underscore the importance of vigilant post-vaccination monitoring in autoimmune populations.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 10","pages":"Article 103857"},"PeriodicalIF":9.2,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706115","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Breast and gynecological cancer risk in systemic lupus erythematosus: A meta-analysis of cohort studies","authors":"Yuejie Lu ,&nbsp;Hejing Pan ,&nbsp;Chengping Wen ,&nbsp;Lin Huang ,&nbsp;Xuanlin Li","doi":"10.1016/j.autrev.2025.103888","DOIUrl":"10.1016/j.autrev.2025.103888","url":null,"abstract":"<div><h3>Objective</h3><div>To evaluate the association between systemic lupus erythematosus (SLE) and the risk of breast and gynecological cancers through a systematic review and meta-analysis of cohort studies.</div></div><div><h3>Methods</h3><div>A comprehensive search was conducted in PubMed, Embase, and the Cochrane Library. The quality of the studies was assessed using the Newcastle-Ottawa Scale (NOS). Statistical analyses were performed, with separate analyses for standardized incidence ratios (SIRs) and 95 % confidence intervals (CIs). Sensitivity analyses, publication bias assessment using funnel plots and Egger's regression test, and subgroup analyses were conducted.</div></div><div><h3>Results</h3><div>The meta-analysis found no significant association between SLE and risk of breast cancer (SIR = 0.84, 95 % CI 0.64–1.11), I² = 97.8 %, <em>P</em> = 0.000) or ovarian cancer (SIR = 0.96, 95 % CI 0.72–1.28, I² = 60.9 %, <em>P</em> = 0.003). However, a significant increase in uterine cancer risk was observed (SIR = 1.41, 95 % CI 1.09–1.82, I² = 94.3 %, <em>P</em> = 0.000). The strongest association was found for vaginal/vulvar cancer (SIR = 3.61, 95 % CI 2.41–5.41, I² = 66.6 %, <em>P</em> = 0.006). Subgroup analyses indicated significant regional variations. European patients showed reduced breast cancer risk (SIR = 0.73, 95 % CI 0.57–0.94), while no significant association was observed in Asian or North American populations. Patients from developed countries had lower ovarian cancer risk than those from developing countries (SIR = 0.82, 95 % CI 0.59–1.60).</div></div><div><h3>Conclusion</h3><div>SLE is associated with an increased risk of uterine and vaginal/vulvar cancers, but not with breast or ovarian cancers. Subgroup analyses reveal regional differences in the relationship between SLE and breast/gynecological cancers.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 11","pages":"Article 103888"},"PeriodicalIF":9.2,"publicationDate":"2025-07-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144694787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Intersection of immune signaling and cell death: The bidirectional regulatory mechanism of STING pathway and Ferroptosis","authors":"Yuxuan Yao ,&nbsp;Xu He ,&nbsp;Yidan Zhu ,&nbsp;Yiru Gong ,&nbsp;Xuchen Song ,&nbsp;Jiali Chen ,&nbsp;Nan Guo ,&nbsp;Yinyu Zhao ,&nbsp;Jing Guo ,&nbsp;Xingxian Luo ,&nbsp;Xiaohong Zhang ,&nbsp;Lin Huang","doi":"10.1016/j.autrev.2025.103877","DOIUrl":"10.1016/j.autrev.2025.103877","url":null,"abstract":"<div><div>The STING signaling pathway is a central component of the innate immune system, primarily responsible for sensing cytosolic DNA and triggering type I interferon responses to regulate innate immune signaling. Recent studies have revealed that, beyond its roles in immune responses, inflammation, and infection, STING can also regulate metabolism and cell death through classical or non-classical signaling pathways. Ferroptosis, a unique iron-dependent form of cell death characterized by intracellular iron accumulation and lipid peroxidation, has been implicated in various diseases, including cancer, autoimmune diseases, neurodegenerative disorders, and infections. Emerging research has demonstrated a correlation between STING and ferroptosis. STING activation induces the production of inflammatory factors and cytokines, which disrupt iron homeostasis, lipid metabolism, and oxidative balance, thereby triggering ferroptosis. Meanwhile, key proteins like GPX4 and ACSL4 in ferroptosis along with certain metabolic products can also influence the activity of the STING signaling pathway. The regulatory direction and signaling intensity of these interactions significantly impact disease states. As a result, deciphering their molecular mechanisms is critical for developing precise therapeutic strategies. Here, we provide a comprehensive overview of the latest research advances related to the STING signaling pathway and ferroptosis, with a particular emphasis on the molecular mechanisms underlying their mutual regulation. In addition, we discuss therapeutic strategies targeting STING signaling and ferroptosis in disease pathology, thereby highlighting their prospective clinical significance in conditions such as cancer and autoimmune diseases.</div></div>","PeriodicalId":8664,"journal":{"name":"Autoimmunity reviews","volume":"24 10","pages":"Article 103877"},"PeriodicalIF":9.2,"publicationDate":"2025-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144681925","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}